Leukocyte Dysfunction in Diabetic Patients.
The purpose of this study is to study impairment of white blood cell function in patients with type II diabetes.
Diabetes Mellitus, Type 2
|Official Title:||Leukocyte Dysfunction in Diabetic Patients.|
- Ex vivo leukocyte function by measuring ROS production [ Time Frame: immediately after blood draw ] [ Designated as safety issue: No ]After blood draw monocytes are separated from whole blood and production of oxidants by these cells
- Ex vivo NADPH oxidase gene and protein expression [ Time Frame: After blood draw ] [ Designated as safety issue: No ]Gene and protein expressions are measured using Western blot and real time PCR.
Biospecimen Retention: Samples With DNA
|Study Start Date:||March 2010|
|Estimated Study Completion Date:||August 2016|
|Estimated Primary Completion Date:||August 2016 (Final data collection date for primary outcome measure)|
Healthy subjects that do not have diabetes
Type II Diabetes (HbA1c <7 or 7%)
Subject that have Type II Diabetes with good glucose control with glycated hemoglobin (HbA1c <7 or 7%)
Type II Diabetes (HbA1c between 7.1-9)
Subjects with Type II Diabetes with moderate glucose control (HbA1c between 7.1-9)
Type II Diabetes (HbA1c >9%)
Subjects with Type II Diabetes with poor glucose control (HbA1c >9%)
Leucocytes from poorly controlled diabetes exhibit aberrant chemotaxis, increased susceptibility to bacterial infection, leukotriene production, lysosomal enzyme release, proinflammatory cytokine expression and production of reactive oxygen species. Aberrant glucose concentration in diabetics affects functions of peripheral blood system as well as the immune system leading to impaired host defense. Impaired wound healing is a serious complication associated with diabetes. We hypothesized that impairment in leukocyte function results in dysfunctional inflammatory response in diabetic wounds. The proposed studies focus on characterizing mechanisms that will improve our understanding of the dysfunctional inflammatory response resulting in non-healing chronic wounds in diabetics.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01144520
|United States, Ohio|
|Ohio State University Comprehensive Wound Center|
|Columbus, Ohio, United States, 43221|
|Principal Investigator:||Roy Sashwati, MS, PhD||Ohio State University Dept of Surgery|